Patent application number | Description | Published |
20090068193 | Treatment And Prophylaxis With 4-1BB-Binding Agents - Materials and Methods for using 4-1BB agonists to treat or prevent autoimmune disorders, lymphoproliferative diseases, and allergies are provided. | 03-12-2009 |
20090092640 | Increased T-cell tumor infiltration and eradication of metastases by mutant LIGHT - Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed. | 04-09-2009 |
20090093429 | COMBINATION THERAPY FOR TREATING CANCER - The invention relates to treatment of primary and secondary tumors using a therapeutic combination including ionizing radiation and gene therapy comprising mutant-LIGHT. Methods of treating a tumor and inducing an anti-tumor immune response are also provided. | 04-09-2009 |
20110014152 | INCREASED T-CELL TUMOR INFILTRATION AND ERADICATION OF METASTASES BY MUTANT LIGHT - Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed. | 01-20-2011 |
20110020340 | ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases. | 01-27-2011 |
20120014947 | METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM - One side-effect arising from the use of antibodies against TNF receptor family members as therapeutics can be liver damage which precludes the completion of clinical trial. A novel LT-dependent pathway is described that mediates liver cell injury in several disease models. | 01-19-2012 |
20120328558 | ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases. | 12-27-2012 |
20150056219 | METHODS AND COMPOSITIONS FOR CANCER THERAPY USING MUTANT LIGHT MOLECULES WITH INCREASED AFFINITY TO RECEPTORS - Methods and compositions are disclosed to target tumor cells with embodiments of the LIGHT proteins linked fused or conjugated to a targeting agent. These compositions bind to both human and mouse receptors with affinity sufficient to conduct preclinical and clinical trials, and with increased affinity as compared to the wild type human LIGHT protein. The targeting of embodiments of LIGHT to tumor cells reduces tumor growth and reduces metastases. | 02-26-2015 |